Supernus Pharmaceuticals, Inc.

This study tested an experimental drug called SAGE-547 in 25 people with super-refractory status epilepticus, a life-threatening condition where seizures don't stop even with strong medications. The main goal was to check if the drug is safe and tolerable when added to standard t…

This study tested a drug called SAGE-718 in 69 people with early Huntington's disease to see if it could improve thinking and daily functioning. Participants took the drug or a placebo for 28 days. The main goal was to measure changes in cognitive abilities like memory and proble…

This study tested an experimental drug called SAGE-547 in 132 people with super-refractory status epilepticus—a life-threatening condition where seizures continue despite strong sedative medications. The goal was to see if SAGE-547 could help patients safely stop those strong sed…

This study tested an experimental drug called SAGE-718 in 189 adults with Huntington's disease to see if it could improve thinking skills like attention, processing speed, and memory. Participants took either the drug or a placebo daily for a period, and their cognitive performan…

This study tested an experimental medicine called SAGE-547 in 21 women with severe postpartum depression. The goal was to see if a single injection could quickly reduce depression symptoms compared to a placebo. The trial was small and early-stage, but results could lead to faste…

This study looked at whether Qelbree (SPN-812) helps adults with ADHD who also have mood symptoms. 161 adults took part and received the medication. Researchers tracked changes in ADHD symptoms using a standard rating scale.

This study tested a drug called SAGE-718 in 26 people with mild memory loss or early Alzheimer's. The main goal was to see if the drug is safe and tolerable, and to check if it helps with thinking, memory, or mood. Participants took the drug and were monitored for side effects an…

This study tested an experimental drug called SAGE-718 to see if it could improve thinking and memory in people with Parkinson's disease who have mild cognitive impairment. 86 participants took either the drug or a placebo. The main goal was to measure changes in processing speed…

This study tested a new medicine called SAGE-547 in 138 women with severe postpartum depression. The medicine was given as a 60-hour IV drip to see if it could quickly reduce depression symptoms compared to a placebo. The goal was to help new mothers feel better within days, not …

This early study tested a single 6-hour intravenous dose of brexanolone in 10 adults with tinnitus (ringing in the ears). The main goal was to check safety and tolerability, with a secondary look at whether the drug reduces perceived loudness. Results are not yet available, but t…

This study tested an experimental drug called SAGE-718 in 174 people with mild cognitive impairment or mild dementia due to Alzheimer's disease. The goal was to see if the drug could improve thinking skills, like processing speed, compared to a placebo. The trial is now complete,…

This study tested a medicine called SAGE-547 given as a 60-hour IV drip to women with moderate or severe postpartum depression. 108 women took part. The goal was to see if it could quickly reduce depression symptoms compared to a placebo. Results showed improvement in depression …

This study tested a drug called brexanolone in teenage girls who had depression after giving birth. The goal was to see if the drug was safe and how the body processes it. 28 participants were enrolled, and the study is now complete.

This early study tested an experimental drug called SAGE-547 in 4 women with severe postpartum depression. The main goal was to see if the injection was safe and how the body processed it. Researchers also looked for signs that symptoms improved, but the study was too small to dr…

This study tested a new drug called SPN-810 in 78 children aged 6 to 12 who have both ADHD and serious conduct problems, like fighting or destroying property. The main goal was to see if different doses of the drug are safe and tolerable. Researchers measured behavior changes usi…

This study looked at whether the drug ZULRESSO (brexanolone) can be safely given to women with postpartum depression in their own homes instead of a clinic. Fifty-two women took part, and researchers tracked side effects and whether the safety rules were followed. The goal was to…

This study tested a new medicine called SAGE-718 in 18 people with Parkinson's disease who also have mild memory or thinking problems. The main goal was to see if the drug is safe and tolerable, and to check if it helps with thinking, mood, and movement. The study was completed a…

This early-stage study tested the safety and tolerability of an experimental drug called SAGE-718 in 6 people: healthy adults and patients with Huntington's disease. The main goal was to check for side effects and how the drug moves through the body. It was a Phase 1 trial, meani…

This early-stage study tested a single dose of the experimental drug SAGE-718 in 22 healthy adults. Researchers used a ketamine challenge to see how the drug affects brain electrical activity, safety, and how the body processes it. The goal was to gather information, not to treat…

This early-stage study tested an experimental drug called SAGE-718 in 19 healthy adults to see how it affects brain chemicals when combined with ketamine. Participants received the drug or a placebo and had brain scans (MRI) to measure changes. The goal was to gather safety and b…

This early-stage study tested an experimental drug called SAGE-718 in 40 healthy adults. Researchers used a ketamine challenge to see how the drug affects brain activity and safety. The goal was to gather information, not to treat any disease.

This early-stage study tested an experimental drug called SAGE-904 in 22 healthy adults to see how it affects brain electrical activity. Participants received either the drug or a placebo, then were given ketamine to temporarily change brain patterns. The goal was to measure brai…